Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer

Gynecologic Oncology

Volumn 124, Issue 3, 2012, Pages 582-588

  Montavon, Céline ^a,b   Gloss, Brian S ^a   Warton, Kristina ^a   Barton, Caroline A ^a   Statham, Aaron L ^a   Scurry, James P ^c   Tabor, Bruce ^a   Nguyen, Tuan V ^a,d   Qu, Wenja ^a   Samimi, Goli ^a,d   Hacker, Neville F ^d,e   Sutherland, Robert L ^a,d   Clark, Susan J ^a,d   O'Brien, Philippa M ^a,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Hunter Area Medical Service   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

DNA methylation; HOXA9; Ovarian cancer; Screening

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; PLATINUM; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR HOXA9; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DNA METHYLATION; FEMALE; HIGH GRADE SEROUS OVARY CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84856711573     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.026     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. C.N. Landen Jr., M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol 26 2008 995 1005
3. L.J. Havrilesky, C.M. Whitehead, J.M. Rubatt, R.L. Cheek, J. Groelke, and Q. He Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence Gynecol Oncol 110 2008 374 382
4. R.C. Bast Jr., D. Badgwell, Z. Lu, R. Marquez, D. Rosen, and J. Liu New tumor markers: CA125 and beyond Int J Gynecol Cancer 15 Suppl. 3 2005 274 281
5. C.A. Barton, N.F. Hacker, S.J. Clark, and P.M. O'Brien DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment Gynecol Oncol 109 2008 129 139
6. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
7. I. Ibanez de Caceres, C. Battagli, M. Esteller, J.G. Herman, E. Dulaimi, and M.I. Edelson Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients Cancer Res 64 2004 6476 6481
8. K.N. Rand, T. Ho, W. Qu, S.M. Mitchell, R. White, and S.J. Clark Headloop suppression PCR and its application to selective amplification of methylated DNA sequences Nucleic Acids Res 33 2005 e127
9. S.J. Clark, A. Statham, C. Stirzaker, P.L. Molloy, and M. Frommer DNA methylation: bisulphite modification and analysis Nat Protoc 1 2006 2353 2364
10. J. Devaney, C. Stirzaker, W. Qu, J.Z. Song, A.L. Statham, and K.I. Patterson Epigenetic deregulation across 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers Cancer Epidemiol Biomarkers Prev 20 2010 148 159
11. R-DevelopmentCoreTeam R: A language and environment for statistical computing 2010 R Foundation for Statistical Computing Vienna, Austria
12. T. Bianco, G. Chenevix-Trench, D.C. Walsh, J.E. Cooper, and A. Dobrovic Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer Carcinogenesis 21 2000 147 151
13. J. Kwong, J.Y. Lee, K.K. Wong, X. Zhou, D.T. Wong, and K.W. Lo Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer Neoplasia 8 2006 268 278
14. R.L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, and S. Narod BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study Cancer Res 60 2000 5329 5333
15. K. Wakana, Y. Akiyama, T. Aso, and Y. Yuasa Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis Cancer Lett 241 2006 281 288
16. Q. Wu, R.A. Lothe, T. Ahlquist, I. Silins, C.G. Trope, and F. Micci DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets Mol Cancer 6 2007 45
17. M. Kaneuchi, M. Sasaki, Y. Tanaka, H. Shiina, M. Verma, and Y. Ebina Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer Biochem Biophys Res Commun 316 2004 1156 1162
18. E.A. Jarboe, A.K. Folkins, R. Drapkin, T.A. Ince, E.S. Agoston, and C.P. Crum Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective Histopathology 53 2008 127 138
19. K. Levanon, C. Crum, and R. Drapkin New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 2008 5284 5293
20. K. Levanon, V. Ng, H.Y. Piao, Y. Zhang, M.C. Chang, and M.H. Roh Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis Oncogene 29 2010 1103 1113
21. H. Du, and H.S. Taylor Molecular regulation of mullerian development by Hox genes Ann N Y Acad Sci 1034 2004 152 165
22. H.S. Taylor, G.B. Vanden Heuvel, and P. Igarashi A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes Biol Reprod 57 1997 1338 1345
23. W. Cheng, J. Liu, H. Yoshida, D. Rosen, and H. Naora Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract Nat Med 11 2005 531 537
24. M.W. Coolen, C. Stirzaker, J.Z. Song, A.L. Statham, Z. Kassir, and C.S. Moreno Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity Nat Cell Biol 12 2010 235 246
25. K. Herrup, C. Murcia, F. Gulden, B. Kuemerle, and N. Bilovocky The genetics of early cerebellar development: networks not pathways Prog Brain Res 148 2005 21 27
26. R. Mayor, L. Casadome, D. Azuara, V. Moreno, S.J. Clark, and G. Capella Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease Br J Cancer 100 2009 1534 1539
27. J. Bolivar, J. Pearson, L. Lopez-Onieva, and A. Gonzalez-Reyes Genetic dissection of a stem cell niche: the case of the Drosophila ovary Dev Dyn 235 2006 2969 2979
28. T.J. Seng, N. Currey, W.A. Cooper, C.S. Lee, C. Chan, and L. Horvath DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma Br J Cancer 99 2008 375 382
29. TCGA Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
30. D.L. Clarke-Pearson Clinical practice. Screening for ovarian cancer N Engl J Med 361 2009 170 177